Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / LXRX - Lexicon's Sotagliflozin: New Approach To Safety May Make Approval Easier

LXRX - Lexicon's Sotagliflozin: New Approach To Safety May Make Approval Easier

Lexicon Pharmaceuticals Inc.
  • Sotagliflozin was rejected by the FDA in 2019 citing diabetic ketoacidosis in type 1 diabetes patients.
  • This time, the company has a new approach and some strong CV benefits data that may change the FDA's viewpoint.
  • The stock has had a marathon run in the last 3-4 months.

For further details see:

Lexicon's Sotagliflozin: New Approach To Safety May Make Approval Easier
Stock Information
Company Name: Lexicon Pharmaceuticals Inc.
Stock Symbol: LXRX
Market: NASDAQ
Website: lexpharma.com
Menu
LXRX LXRX Quote LXRX Short LXRX News LXRX Articles LXRX Message Board
Get LXRX Alerts

News, Short Squeeze, Breakout and More Instantly...